

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

August 2014

Vol. 42, No. 8

CONTENTS

SHORT COMMUNICATION

- Interactions of Endosulfan and Methoxychlor Involving CYP3A4 and CYP2B6 in Human HepaRG Cells. *Camille C. Savary, Rozenn Jossé, Arnaud Bruyère, Fabrice Guillet, Marie-Anne Robin, and André Guillouzo* **1235**

ARTICLES

- The Revised Human Liver Cytochrome P450 "Pie": Absolute Protein Quantification of CYP4F and CYP3A Enzymes Using Targeted Quantitative Proteomics. *Scott Michaels and Michael Zhuo Wang* **1241**

- Identification of Metabolites of *N*-(5-Benzoyl-2-(4-(2-Methoxyphenyl)piperazin-1-yl)thiazol-4-yl) pivalamide Including CYP3A4-Mediated *C*-Demethylation in Human Liver Microsomes with High-Resolution/High-Accuracy Tandem Mass. *Min Song, Doohyun Lee, Sun Kim, Jong-Sup Bae, Jaeick Lee, Young-Dae Gong, Taeho Lee, and Sangkyu Lee* **1252**

- Different Binding Sites of Bovine Organic Anion-Transporting Polypeptide1a2 Are Involved in the Transport of Different Fluoroquinolones. *Yunpeng Xiao, Jifeng Deng, Xiaoxiao Liu, Jiujiu Huang, Yongxue Sun, Renke Dai, and Mei Hong* **1261**

- Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters. *Miriam G. Mooij, Ute I. Schwarz, Barbara A. E. de Koning, J. Steven Leeder, Roger Gaedigk, Janneke N. Samsom, Edwin Spaans, Johannes B. van Goudoever, Dick Tibboel, Richard B. Kim, and Saskia N. de Wildt* **1268**

- Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate. *Voon Ong, Shawn Flanagan, Edward Fang, Howard J. Dreskin, Jeffrey B. Locke, Kenneth Bartizal, and Philippe Prokocimer* **1275**

- Treatment with a Monoclonal Antibody against Methamphetamine and Amphetamine Reduces

- Maternal and Fetal Rat Brain Concentrations in Late Pregnancy. *Sarah J. White, Howard P. Hendrickson, William T. Atchley, Elizabeth M. Laurenzana, W. Brooks Gentry, D. Keith Williams, and S. Michael Owens* **1285**

- Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases. *Shruthi Vaidhyanathan, Rajendar K. Mittapalli, Jann N. Sarkaria, and William F. Elmquist* **1292**

- Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. *Laurent Salphati, Xiaoyan Chu, Liangfu Chen, Bhagwat Prasad, Shannon Dallas, Raymond Evers, Donna Mamaril-Fishman, Ethan G. Geier, Jonathan Kehler, Jeevan Kunta, Mario Mezler, Loic Laplanche, Jodie Pang, Anja Rode, Matthew G. Soars, Jashvant D. Unadkat, Robert A. B. van Waterschoot, Jocelyn Yabut, Alfred H. Schinkel, and Nico Scheer* **1301**

- Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling. *Donna Mamaril-Fishman, John Zhu, Min Lin, Clive Felgate, Lori Jones, Patrick Stump, Esaie Pierre, Chester Bowen, Odin Naderer, Etienne Dumont, Parul Patel, Peter D. Gorycki, Bo Wen, Liangfu Chen, and Yanli Deng* **1314**

- Oxidative Metabolic Pathway of Lenvatinib Mediated by Aldehyde Oxidase. *Kazuko Inoue, Hitoshi Mizuo, Shinki Kawaguchi, Katsuyuki Fukuda, Kazutomi Kusano, and Tsutomu Yoshimura* **1326**

- In Vitro Oxidative Metabolism of 6-Mercaptopurine in Human Liver: Insights into the Role of the Molybdoflavoenzymes Aldehyde Oxidase, Xanthine Oxidase, and Xanthine Dehydrogenase. *Kanika V. Choughule, Carlo Barnaba, Carolyn A. Joswig-Jones, and Jeffrey P. Jones* **1334**

Continued on next page

- ☐ Generation and Characterization of a Novel CYP2A13-Transgenic Mouse Model. *Kunzhi Jia, Lei Li, Zihua Liu, Matthew Hartog, Kerri Kluetzman, Qing-Yu Zhang, and Xinxin Ding 1341*
- ☐ Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis. *Brahim Achour, Jill Barber, and Amin Rostami-Hodjegan 1349*

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Strategy for modification of the *CYP2A13/2B6/2F1* BAC clone to inactivate *CYP2F1* and *CYP2B6* and structure of the transgene. See the article by Jia et al., ([dx.doi.org/10.1124/dmd.114.059188](https://doi.org/10.1124/dmd.114.059188)).